These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38466720)

  • 1. Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort Study.
    Romine JK; Li H; Coughlin MM; Jones JM; Britton A; Tyner HL; Fuller SB; Bloodworth R; Edwards LJ; Etolue JN; Morrill TC; Newes-Adeyi G; Olsho LEW; Gaglani M; Fowlkes A; Hollister J; Bedrick EJ; Uhrlaub JL; Beitel S; Sprissler RS; Lyski Z; Porter CJ; Rivers P; Lutrick K; Caban-Martinez AJ; Yoon SK; Phillips AL; Naleway AL; Burgess JL; Ellingson KD
    Clin Infect Dis; 2024 Jul; 79(1):96-107. PubMed ID: 38466720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody response to SARS-CoV-2 mRNA vaccination in Danish adults exposed to perfluoroalkyl substances (PFASs): The ENFORCE study.
    Timmermann A; Johansen IS; Tolstrup M; Heilmann C; Budtz-Jørgensen E; Tolstrup JS; Nielsen F; Grandjean P
    Environ Res; 2024 Dec; 263(Pt 1):120039. PubMed ID: 39326653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
    Madhi SA; Kwatra G; Myers JE; Jassat W; Dhar N; Mukendi CK; Nana AJ; Blumberg L; Welch R; Ngorima-Mabhena N; Mutevedzi PC
    N Engl J Med; 2022 Apr; 386(14):1314-1326. PubMed ID: 35196424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March-December 2021.
    Katz MA; Rojas Castro MY; Chakhunashvili G; Chitadze N; Ward CL; McKnight CJ; Lucaccioni H; Finci I; Zardiashvili T; Pebody R; Kissling E; Sanodze L
    PLoS One; 2024; 19(9):e0307805. PubMed ID: 39240827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
    Rizvi NB; Bibi M; Rana MZ; Zaffar S; Farooq H
    Front Immunol; 2024; 15():1448408. PubMed ID: 39606247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
    Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G;
    Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Goswami J; Cardona JF; Hsu DC; Simorellis AK; Wilson L; Dhar R; Tomassini JE; Wang X; Kapoor A; Collins A; Righi V; Lan L; Du J; Zhou H; Stoszek SK; Shaw CA; Reuter C; Wilson E; Miller JM; Das R;
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39608389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
    Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
    JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from
    Niu M; Mu Y; Adriko M; Candia R; Jones MK; McManus DP; Egwang TG; Cai P
    Front Public Health; 2024; 12():1437063. PubMed ID: 39624416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY.
    Pearce FA; Lim SH; Bythell M; Lanyon P; Hogg R; Taylor A; Powter G; Cooke GS; Ward H; Chilcot J; Thomas H; Mumford L; McAdoo SP; Pettigrew GJ; Lightstone L; Willicombe M
    Lancet Rheumatol; 2023 Aug; 5(8):e461-e473. PubMed ID: 38251578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
    Feldstein LR; Britton A; Grant L; Wiegand R; Ruffin J; Babu TM; Briggs Hagen M; Burgess JL; Caban-Martinez AJ; Chu HY; Ellingson KD; Englund JA; Hegmann KT; Jeddy Z; Lauring AS; Lutrick K; Martin ET; Mathenge C; Meece J; Midgley CM; Monto AS; Newes-Adeyi G; Odame-Bamfo L; Olsho LEW; Phillips AL; Rai RP; Saydah S; Smith N; Steinhardt L; Tyner H; Vandermeer M; Vaughan M; Yoon SK; Gaglani M; Naleway AL
    JAMA; 2024 Feb; 331(5):408-416. PubMed ID: 38319331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis.
    Martin CA; Nazareth J; Jarkhi A; Pan D; Das M; Logan N; Scott S; Bryant L; Abeywickrama N; Adeoye O; Ahmed A; Asif A; Bandi S; George N; Gohar M; Gray LJ; Kaszuba R; Mangwani J; Martin M; Moorthy A; Renals V; Teece L; Vail D; Khunti K; Moss P; Tattersall A; Hallis B; Otter AD; Rowe C; Willett BJ; Haldar P; Cooper A; Pareek M
    EClinicalMedicine; 2023 Apr; 58():101926. PubMed ID: 37034357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
    Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
    Laxminarayan R; B CM; G VT; Arjun Kumar KV; Wahl B; Lewnard JA
    Lancet Infect Dis; 2021 Dec; 21(12):1665-1676. PubMed ID: 34399090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing antibody response after COVID-19 recombinant protein vaccination in adults: A cross-sectional observational study, in Chongqing, China.
    Li J; Xu J; Liu Y; Chen L; Yu L; Xiao X; Wang Q
    Hum Vaccin Immunother; 2024 Dec; 20(1):2389602. PubMed ID: 39171541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.